FGF-23 is associated with cardiac troponin T and mortality in hemodialysis patients

Hemodialysis International

Volumn 16, Issue 1, 2012, Pages 53-58

  Holden, Rachel M ^a   Beseau, David ^a   Booth, Sarah L ^b   Adams, Michael A ^a   Garland, Jocelyn S ^a   Morton, Ross A ^a   Collier, Christine P ^a   Foley, Robert N ^c  

^a QUEEN S UNIVERSITY   (Canada)

^b TUFTS UNIVERSITY   (United States)

^c MINNEAPOLIS MEDICAL RESEARCH FOUNDATION   (United States)

Author keywords

FGF 23; Hemodialysis; Mortality; Troponin T

Indexed keywords

ALBUMIN; FIBROBLAST GROWTH FACTOR 23; PHOSPHORUS; TROPONIN T;

ADULT; AGE; ARTICLE; COHORT ANALYSIS; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HEART LEFT VENTRICLE HYPERTROPHY; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE;

ADULT; AGED; FEMALE; FIBROBLAST GROWTH FACTORS; HUMANS; MALE; MIDDLE AGED; PHOSPHORUS; RENAL DIALYSIS; TROPONIN T;

EID: 84856368350     PISSN: 14927535     EISSN: 15424758     Source Type: Journal    
DOI: 10.1111/j.1542-4758.2011.00630.x     Document Type: Article

References (27)

1. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis. 1998; 32(Suppl 3):S112-S119.
2. Raggi P, Kleerekoper M. Contribution of bone and mineral abnormalities to cardiovascular disease in patients with chronic kidney disease. Clin J Am Soc Nephrol. 2008; 3:836-843.
3. Sigrist MK, Taal MW, Bungay P, McIntyre CW. Progressive vascular calcification over 2 years is associated with arterial stiffening and increased mortality in patients with stages 4 and 5 chronic kidney disease. Clin J Am Soc Nephrol. 2007; 2:1241-1248.
4. Jindal K, Chan CT, Deziel C etal. Hemodialysis clinical practice guidelines for the Canadian Society of Nephrology. J Am Soc Nephrol. 2006; 3(Suppl 1):S1-27.
5. Gutierrez O, Isakova T, Rhee E etal. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol. 2005; 16:2205-2215.
6. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004; 15:2208-2218.
7. Young EW, Albert JM, Satayathum S etal. Predictors and consequences of altered mineral metabolism: The Dialysis Outcomes and Practice Patterns Study. Kidney Int. 2005; 67:1179-1187.
8. Stevens LA, Djurdjev O, Cardew S, Cameron EC, Levin A. Calcium, phosphate, and parathyroid hormone levels in combination and as a function of dialysis duration predict mortality: Evidence for the complexity of the association between mineral metabolism and outcomes. J Am Soc Nephrol. 2004; 15:770-779.
9. Slinin Y, Foley RN, Collins AJ. Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients: The USRDS waves 1, 3, and 4 study. J Am Soc Nephrol. 2005; 16:1788-1793.
10. London GM, Guerin AP, Marchais SJ, Metivier F, Pannier B, Adda H. Arterial media calcification in end-stage renal disease: Impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant. 2003; 18:1731-1740.
11. Ferrari SL, Bonjour JP, Rizzoli R. Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men. J Clin Endocrinol Metab. 2005; 90:1519-1524.
12. Gutierrez OM, Mannstadt M, Isakova T etal. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. New Engl J Med. 2008; 359:584-592.
13. Jean G, Terrat JC, Vanel T etal. High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients. Nephrol Dial Transplant. 2009; 24:2792-2796.
14. Gutierrez OM, Januzzi JL, Isakova T etal. Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation. 2009; 119:2545-2552.
15. Negishi K, Kobayashi M, Ochiai I etal. Association between fibroblast growth factor 23 and left ventricular hypertrophy in maintenance hemodialysis patients. Comparison with B-type natriuretic peptide and cardiac troponin T. Circ J. 2010; 74:2734-2740.
16. Hsu HJ, Wu MS. Fibroblast growth factor 23: A possible cause of left ventricular hypertrophy in hemodialysis patients. Am J Med Sci. 2009; 337:116-122.
17. Mirza MA, Larsson A, Melhus H, Lind L, Larsson TE. Serum intact FGF23 associate with left ventricular mass, hypertrophy and geometry in an elderly population. Atherosclerosis. 2009; 207:546-551.
18. Kawata T, Imanishi Y, Kobayashi K etal. Parathyroid hormone regulates fibroblast growth factor-23 in a mouse model of primary hyperparathyroidism. J Am Soc Nephrol. 2007; 18:2683-2688.
19. Petrovic D, Stojimirovic BB. Cardiac troponins: Outcome predictors in hemodialysis patients. J Artif Organs. 2009; 12:258-263.
20. Desai AA, Nissenson A, Chertow GM etal. The relationship between laboratory-based outcome measures and mortality in end-stage renal disease: A systematic review. Hemodial Int. 2009; 13:347-359.
21. Bagheri N, Taziki O, Falaknazi K. C-reactive protein, cardiac troponin T and low albumin are predictors of mortality in hemodialysis patients. Saudi J Kidney Dis Transpl. 2009; 20:789-793.
22. Khouri MG, Peshock RM, Ayers CR, de Lemos JA, Drazner MH. A 4-tiered classification of left ventricular hypertrophy based on left ventricular geometry: The Dallas heart study. Circ Cardiovasc Imaging. 2010; 3:164-171.
23. Resic H, Ajanovic S, Kukavica N, Masnic F, Coric A. Plasma levels of brain natriuretic peptides and cardiac troponin in hemodialysis patients. Bosn J Basic Med Sci. 2009; 9:137-141.
24. Wang AY, Lam CW, Wang M etal. Diagnostic potential of serum biomarkers for left ventricular abnormalities in chronic peritoneal dialysis patients. Nephrol Dial Transplant. 2009; 24:1962-1969.
25. Foley RN, Collins AJ, Herzog CA, Ishani A, Kalra PA. Serum phosphate and left ventricular hypertrophy in young adults: The coronary artery risk development in young adults study. Kidney Blood Press Res. 2009; 32:37-44.
26. Marchais SJ, Metivier F, Guerin AP, London GM. Association of hyperphosphataemia with haemodynamic disturbances in end-stage renal disease. Nephrol Dial Transplant. 1999; 14:2178-2183.
27. Vatner SF. FGF induces hypertrophy and angiogenesis in hibernating myocardium. Circ Res. 2005; 96:705-707.